The core activity of Jantar GmbH is the development of pharmaceutical products, particularly research and development (R&D) of medications for the treatment of rhinosinusitis, specifically with the active ingredient JT-1 for nasal spray application.
AI-generated
Offering
Products & services
Industry:Pharmaceutical Industry
✓ Offered3
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Development of Dicholinsuccinate for chronic rhinosinusitis
Preclinical development, active substance synthesis, drug product manufacturing, analytics, stability and toxicology for Dicholinsuccinate as a nasal spray for chronic rhinosinusitis.
Clinical development and Phase III studies
Proof-of-concept studies in patients with chronic rhinosinusitis as well as planned controlled, randomized Phase III study as a basis for marketing authorization.
Licensing and cooperation for consumer health partners
Search for an international partner for a licensing and cooperation agreement to continue the clinical and commercial development of a nasal spray.
Knowledge
No knowledge articles yet
Once Jantar GmbH has claimed this profile, we'll publish editorial articles and case studies here together.